PMID- 35466184
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2038-8322 (Print)
IS  - 2038-8330 (Electronic)
IS  - 2038-8322 (Linking)
VI  - 14
IP  - 2
DP  - 2022 Apr 13
TI  - Prompt Hematological Recovery in Response to a Combination of Pegylated 
      Interferon alpha-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell 
      Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks 
      of Rapid Immune Reconstitution.
PG  - 135-142
LID - 10.3390/hematolrep14020020 [doi]
AB  - The present paper reports, to the best of our knowledge for the first time, the 
      efficacy and tolerability of the combination of interferon (IFN)alpha-2a in pegylated 
      formulation and rituximab after a "priming" phase with IFN in the frontline 
      treatment of hairy cell leukemia (HCL) in a profoundly immunosuppressed patient 
      with a Mycobacterium abscessus infection at onset. This immunotherapy combination 
      may represent a potential therapeutic option in patients with active severe 
      infection and for whom the use of purine nucleoside analogues (PNA) is 
      contraindicated. The benefits and drawbacks of remarkably rapid immune 
      reconstitution in the context of opportunistic infections are highlighted as 
      well, as the potentially paradoxical effects of immune recovery as a result of 
      effective immunotherapy strategies, known as immune reconstitution inflammatory 
      syndrome (IRIS), have to be taken into account when dealing with patients with 
      opportunistic infections.
FAU - Furlan, Anna
AU  - Furlan A
AD  - Hematology Unit, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy.
FAU - Rossi, Maria Cristina
AU  - Rossi MC
AD  - Infectious Disease Unit, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy.
FAU - Gherlinzoni, Filippo
AU  - Gherlinzoni F
AD  - Hematology Unit, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy.
FAU - Scotton, Piergiorgio
AU  - Scotton P
AD  - Infectious Disease Unit, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy.
LA  - eng
PT  - Case Reports
DEP - 20220413
PL  - Switzerland
TA  - Hematol Rep
JT  - Hematology reports
JID - 101556723
PMC - PMC9036287
OTO - NOTNLM
OT  - hairy cell leukemia
OT  - immune reconstitution inflammatory syndrome
OT  - interferon
OT  - opportunistic infections
OT  - rituximab
COIS- The authors declare that they have no competing interests.
EDAT- 2022/04/26 06:00
MHDA- 2022/04/26 06:01
PMCR- 2022/04/13
CRDT- 2022/04/25 06:14
PHST- 2022/02/15 00:00 [received]
PHST- 2022/03/11 00:00 [revised]
PHST- 2022/03/30 00:00 [accepted]
PHST- 2022/04/25 06:14 [entrez]
PHST- 2022/04/26 06:00 [pubmed]
PHST- 2022/04/26 06:01 [medline]
PHST- 2022/04/13 00:00 [pmc-release]
AID - hematolrep14020020 [pii]
AID - hematolrep-14-00020 [pii]
AID - 10.3390/hematolrep14020020 [doi]
PST - epublish
SO  - Hematol Rep. 2022 Apr 13;14(2):135-142. doi: 10.3390/hematolrep14020020.